First Wave BioPharma to Present at the DealFlow MicroCap Conference
January 23, 2024 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma CEO to Present at the Sequire Investor Summit 2024 in Puerto Rico
January 17, 2024 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024
January 04, 2024 06:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Evoke Pharma & EVERSANA Unveil Cost Savings Real-World Data Demonstrating Meaningfully Reduced Healthcare Costs for Patients Using GIMOTI Over Oral Metoclopramide Presented at the American College of Gastroenterology 2023
October 31, 2023 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting
October 24, 2023 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced top line data from an abstract...
Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 Annual Meeting
October 18, 2023 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Reports Second Quarter 2023 Financial Results
August 10, 2023 08:30 ET
|
Evoke Pharma, Inc.
40% revenue growth compared to Q1 2023 34% increase in prescription fills compared to Q1 2023 Presented industry-leading real-world healthcare utilization data supporting the benefits of GIMOTI...
Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting
August 07, 2023 08:30 ET
|
Evoke Pharma, Inc.
Real-world study that explored the healthcare utilization resource utilization among patients receiving GIMOTI with and without prior treatment with oral metoclopramide Both organizations recognize...
Evoke Pharma to Host First Key Opinion Leader Webinar on Healthcare Resource Utilization Data Related to Gastroparesis and its Treatment
June 14, 2023 08:30 ET
|
Evoke Pharma, Inc.
SOLANA BEACH, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with...
Evoke Pharma Reports First Quarter 2023 Financial Results
May 15, 2023 16:05 ET
|
Evoke Pharma, Inc.
Net product sales increased by 94% from Q1 2022New cumulative prescribers up by 17% from Q4 2022Doubled patient enrollment since Q1 2022; 127% increase SOLANA BEACH, Calif., May 15, 2023 (GLOBE...